Knockdown of human bid gene expression enhances survival of CD8+ T cells

Li, Xiaoying; Xu, Yan‐Ming; Wang, Tao; Xie, Qiaosheng; Jia, Lintao; Wang, Lifeng; Jin, Boquan; Zhang, Yan; Yao, Libo; Yang, An‐Gang

doi:10.1016/j.imlet.2008.10.009

Cited by 11 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple reports have underscored the importance of knocking down apoptotic genes (e.g. Bim, Bid, Bax, FasL) to improve T cell longevity [58,[271][272][273][274][275][276][277]. For example, blocking Bid expression in CD8 + T cells using virally expressed siRNAs significantly reduced Fas-induced apoptosis and enhanced T cell survival in low IL-2 concentrations [272].…”

Section: Ex Vivo Therapeutic Potential Of Sirna In Cancer Immunotherapymentioning

confidence: 99%

Non-viral siRNA delivery to T cells: Challenges and opportunities in cancer immunotherapy

et al. 2022

View full text Add to dashboard Cite

Section: Ex Vivo Therapeutic Potential Of Sirna In Cancer Immunotherapymentioning

confidence: 99%

Non-viral siRNA delivery to T cells: Challenges and opportunities in cancer immunotherapy

et al. 2022

View full text Add to dashboard Cite

“…Although many antitumor agents have been used to target the proteins involved in apoptosis to induce cancer cell death or enhance the sensitivity of cancer cells to certain cytotoxic drugs or radiation, targeting of proapoptotic proteins have not been considered enough in CAR T cell therapy to make more persistent CAR T cells. There are many investigations underscoring that targeting proapoptotic protein in T cells can improve T cell longevity (118)(119)(120)(121)(122)(123)(124). Thus, it seems that knocking down or knocking out of proapoptotic proteins such as Bim and/or Bid, by shRNA and siRNA or CRISPR/Cas9 respectively can lead to increased survival of CAR T cells in a similar way to tumor cells which acquire resistance to apoptosis through downregulation or mutation of proapoptotic proteins.…”

Section: Knocking Down Of Proapoptotic Molecules and Overexpression Omentioning

confidence: 99%

Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward

et al. 2020

View full text Add to dashboard Cite

CAR T cell qualities, such as persistence and functionality play important roles in determining the outcome of cancer immunotherapy. In spite of full functionality, it has been shown that poor persistence of CAR T cells can limit an effective antitumor immune response. Here, we outline specific strategies that can be employed to overcome intrinsic and extrinsic barriers to CAR T cell persistence. We also offer our viewpoint on how growing use of CAR T cells in various cancers may require modifications in the intrinsic and extrinsic survival signals of CAR T cells. We anticipate these amendments will additionally provide the rationales for generation of more persistent, and thereby, more effective CAR T cell treatments. CAR T cell qualities, such as persistence and functionality play important roles in determining the outcome of cancer immunotherapy. In spite of full functionality, it has been shown that poor persistence of CAR T cells can limit an effective antitumor immune response. Here, we outline specific strategies that can be employed to overcome intrinsic and extrinsic barriers to CAR T cell persistence. We also offer our viewpoint on how growing use of CAR T cells in various cancers may require modifications in the intrinsic and extrinsic survival signals of CAR T cells. We anticipate these amendments will additionally provide the rationales for generation of more persistent, and thereby, more effective CAR T cell treatments.

show abstract

“…T-cell functions can be significantly improved by genetic modifications such as downregulation of BH3-interacting domain death agonist (BID) [72, 73] or upregulation of BCL-XL and BCL-2 [74, 75], insertion of CTLA4 mutant gene [76], transfection of human c-fms gene for responding to colony-stimulating factor-1 (CSF-1) [77], transduction of C-X-C chemokine receptor type 2 (CXCR2), C-C chemokine receptor type 4 (CCR4) or CCR2B for better migration [78], and modification to express PD1-CD 28 chimaera to overcome immune suppression [79]. In addition, T cells can be equipped with genes that encode receptors capable of recognizing cancer-specific antigen.…”

Section: T-cell-based Cell Transfermentioning

confidence: 99%

Cell Transfer Therapy for Cancer: Past, Present, and Future

Qian

Wang

Jin

2014

Journal of Immunology Research

View full text Add to dashboard Cite

Cell transfer therapy for cancer has made a rapid progress recently and the immunotherapy has been recognized as the fourth anticancer modality after operation, chemotherapy, and radiotherapy. Lymphocytes used for cell transfer therapy include dendritic cells, natural killer (NK) cells, and T lymphocytes such as tumor-infiltrating lymphocytes (TILs) and cytotoxic T lymphocytes (CTLs). In vitro activated or engineered immune cells can traffic to cancer tissues to elicit persistent antitumor immune response which is very important especially after immunosuppressive treatments such as chemotherapy. In this review, we overviewed recent advances in the exploration of dendritic cells, NK cells, and T cells for the treatment of human cancer cells.

show abstract

Knockdown of human bid gene expression enhances survival of CD8+ T cells

Cited by 11 publications

References 29 publications

Non-viral siRNA delivery to T cells: Challenges and opportunities in cancer immunotherapy

Non-viral siRNA delivery to T cells: Challenges and opportunities in cancer immunotherapy

Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward

Cell Transfer Therapy for Cancer: Past, Present, and Future

Contact Info

Product

Resources

About